SENS-401

Sensorion announced it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation. SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.

Methyl 5-chloro-2-hydroxybenzoate

CM157726

4068-78-4

2-(carboxymethoxy)-5-chlorobenzoic acid

CM1075465

334758-22-4

6-Chloro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid

CM634285

123040-45-9

1-Azabicyclo[2.2.2]octan-3-amine, (3R)-

CM431540

123536-15-2